<DOC>
	<DOCNO>NCT02784028</DOCNO>
	<brief_summary>The digestive cancer second cause death worldwide . The presence peritoneal carcinomatosis common evolution type cancer , well increased level ACE . This peritoneal carcinomatosis often underestimated , due low sensitivity detection mean . In recent year , show peritoneal carcinomatosis surgery complete possible associate intraperitoneal chemotherapy give good result still failures associate presence microscopic residual tumor . The use SGM -101 ( developped SURGIMAB SAS ) allow surgeon detect tumor nodule small size easily , real-time , surgery ( show animal ) .</brief_summary>
	<brief_title>Study Patients With Peritoneal Carcinomatosis From CEA Overexpressing Digestive Cancer</brief_title>
	<detailed_description>The digestive cancer second cause death worldwide . The presence peritoneal carcinomatosis common evolution type cancer , well increased level ACE . This peritoneal carcinomatosis often underestimated , due low sensitivity detection mean . In recent year , show peritoneal carcinomatosis surgery complete possible associate intraperitoneal chemotherapy give good result still failures associate presence microscopic residual tumor . SGM -101 ( developped SURGIMAB SAS ) fluorescent antibody bind ACE overespressed surface tumor cell . The use fluorescent molecule allow surgeon detect tumor nodule small size easily , real-time , surgery ( show animal ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<criteria>1 . Cytologically histologic proven primary recurrent digestive adenocarcinoma eligible hyperthermic intraperitoneal chemoperfusion ( HIPEC ) procedure , 2 . Evidence peritoneal carcinomatosis , presume resectable , assessed imaging ( CT scan ( Computed Tomography Scanner ) / MRI ( Magnetic Resonance Imaging ) ) previous abdominal surgery , , 3 . CEA positivity immunohistochemistry specimen primary tumor recurrence lesion , circulate plasma CEA ≥ 2 time upper limit normal range ( ULN ) , 4 . ECOG ( Eastern Cooperative Oncology group ) &lt; 1 5 . Life expectancy least three month , 6 . AST ( Aspartate AminoTransferase ) , ALT ( Alanine AminoTransferase ) Alkaline Phosphatase level ≤ 5 time ULN , 7 . Total bilirubin ≤ 1.5 time ULN , Serum creatinine ≤ 1.5 time ULN , absolute neutrophil count ≥ 1.5 x 109/L , platelet count ≥ 100 x 109/L hemoglobin ≥ 9 g/dL , ( red blood transfusion allow need ) , 8 . Patients age 18 year old , 9 . Patients affiliate French Social Security System , 10 . Signed informed consent ( IC ) obtain study specific procedure . 1 . ASA ( American Society Anesthesiologists ) score ≥ 3 , 2 . Anticancer therapy ( e.g . chemotherapy , radiotherapy , target therapy , concomitant systemic immune therapy , experimental therapy ) within 4 week inclusion , 3 . Known serious immune allergic history , 4 . Rate circulate plasma CEA ≥ 300 ng / ml , 5 . Other malignancy either currently active diagnose last 5 year , except adequately treat situ carcinoma cervix basal squamous cell skin carcinoma . 6 . Female patient pregnant breastfeeding ( pregnancy rule assay βhCG plasma within 7 day prior administration conjugate ) . Patients reproductive potential sexually active must agree least two method contraception duration treatment ( 2 week 8 12 week administration SGM101 ) Male patient , must use effective method contraception ( condom spermicidal foam gel ; true abstinence ; vasectomy throughout study 12 week last SGM101 administration ) . 7 . Known positive test human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAG ) hepatitis C virus ( HCV ) antibody patient untreated serious infection , 8 . Any concurrent and/or uncontrolled medical condition metabolic dysfunction , would , investigator 's judgment contraindicate participation clinical study 9 . Legal incapacity physical , psychological mental status interfere patient 's ability sign inform consent terminate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Peritoneal Carcinomatosis</keyword>
	<keyword>SGM-101</keyword>
</DOC>